Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Omeros Corporation (OMER - Snapshot Report) recently announced that it has commenced enrollment for a phase II study on its pipeline candidate OMS824, after reporting positive data from a phase I study earlier in the month.

We note that OMS824 is the lead compound in Omeros' phosphodiesterase 10 (PDE10) program. Omeros is developing the candidate as a PDE10 inhibitor, which is an enzyme expressed in areas of the brain linked to a wide range of diseases, including Huntington's disease and schizophrenia, affecting cognition.

The phase II trial will evaluate OMS824’s tolerability, safety, pharmacokinetics and potential interactions with other related medications in patients suffering from stable schizophrenia.

The patients will be administered various doses of OMS824 for two weeks to assess the effect of OMS824 as a monotherapy and in combination with other antipsychotic medications. Shares reacted positively to the news of the initiation of the phase II study.

We note that, last week, Omeros released new positive data from a phase I study evaluating the pharmacokinetics of OMS824.

The encouraging data further support the fact that OMS824 can achieve superior target engagement with lesser side effects in comparison to other PDE10 inhibitors in development. Moreover, OMS824 was well tolerated at the highest multiple-dose level administered.

Meanwhile, we remind investors that Omeros is currently looking to get its candidate, OMS302, approved in the U.S. and EU for the treatment of patients undergoing intraocular lens replacement (ILR) surgery.

Omeros expects to launch OMS302 both in the U.S. and the EU in the second half of 2014, pending regulatory approval. 

We are encouraged by the pipeline progress at Omeros.

Omeros currently carries a Zacks Rank #3 (Hold).  Stocks that currently look attractive include Biogen Idec Inc. (BIIB - Analyst Report), Gilead Sciences Inc. (GILD - Analyst Report) and Affymetrix Inc. (AFFX - Analyst Report). All three carry a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%